0
Tobacco Cessation and Prevention |

Continuous Abstinence Rates at 3, 6, 9, and 12 Months for Males, Females, and Overall Sample in a Tobacco Cessation Unit in Albacete University Hospital During 2008 and 2009

Francisco Javier Callejas Gonzalez, PhD; Abel Martinez Garcia, MD; Marta Genoves Crespo, MD; Juan Pastrana Calderon, MD; Mariela Plenc Ziegler, MD; Angel Molina Cano, MD; Sergio Garcia Castillo, MD; Javier Cruz Ruiz, MD; Juan Carlos Ceballos Romero, MD; Ana Isabel Tornero Molina, MD
Author and Funding Information

Complejo Hospitalario Universitario de Albacete - Pneumonology, Albacete, Spain


Chest. 2013;144(4_MeetingAbstracts):1007A. doi:10.1378/chest.1703603
Text Size: A A A
Published online

Abstract

SESSION TITLE: Tobacco Cessation and Prevention

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 27, 2013 at 10:45 AM - 11:45 AM

PURPOSE: Review the results analyzed in a Tobacco Cessation Unit during 2008-2009.

METHODS: Retrospective descriptive analysis of the results obtained from patients who were attended in a Tobacco Cessation Unit from January 1st in 2008 to December 31 in 2009 and the subsequent follow-up to complete a year.

RESULTS: 559 of 838 patients, 53,7% male. S.s. between cigarettes smoked and sex, higher in males (29,48 vs. 24,78, p<0.01). Severe comorbidity: respiratory (34,1%), CVRF (56%) and psychiatric (37,7%). 32,7% without treatment, 34,5% NRT, 9,8% bupropion and 22,9% varenicline. Continuous abstinence rates at 3, 6, 9 and 12 months follow up for males were 51,3%, 37,7%, 32,5% and 30,5% respectively; continuous abstinence rates at 3, 6, 9 and 12 months follow up for females were 45,2%, 29,8%, 25% and 24,2%, respectively, and continuous abstinence rates at 3, 6, 9 and 12 months follow up for overall sample were 48,6%, 34,2%, 29,1% and 27,7%, respectively. Overall of the 559 patients, treatment success (one year without smoking) in 77 (13,8%), 47 men and 30 women; percentage rises to 27,7% if we do not consider those who did not attend the second consultation. Those who were treated pharmacologically, greater success among who used varenicline (5,7%) than NRT (5%) or bupropion (1,4%).

CONCLUSIONS: 1. 66,82% did not start treatment (33,3% and 33,52%, first and second appointment respectively). 2. Cigarette consumption by males was significantly higher than women (29,48 vs. 24,78, p<0,01). 3. Continuous abstinence rates were higher for males than females and overall treatment success was 27,7%. 4. Greater success among varenicline than NRT or bupropion-treated.

CLINICAL IMPLICATIONS: When patients attend our Tobacco Cessation Unit, they have often severe comorbidity. Smoking cessation treatment is effective but it requires patients commitment. There is an overall treatment success of 27,7% excluding those who did not attend the second consultation. In our sample, patients treated with varenicline showed a success rate higher than the ones treated with bupropion or nicotine replacement therapy.

DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas Gonzalez, Abel Martinez Garcia, Marta Genoves Crespo, Juan Pastrana Calderon, Mariela Plenc Ziegler, Angel Molina Cano, Sergio Garcia Castillo, Javier Cruz Ruiz, Juan Carlos Ceballos Romero, Ana Isabel Tornero Molina

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543